Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a severe and progressive neuronal loss leading to cognitive dysfunctions. Previous reports, based on the use of chemical inhibitors, have connected the stress kinase p38α to neuroinflammation, neuronal death and synaptic dysfunction. To explore the specific role of neuronal p38α signalling in the appearance of pathological symptoms, we have generated mice that combine expression of the 5XFAD transgenes to induce AD symptoms with the downregulation of p38α only in neurons (5XFAD/p38α∆-N). We found that the neuronal-specific deletion of p38α improves the memory loss and long-term potentiation impairment induced by 5XFAD transgenes. Furthermore, 5XFAD/p38α∆-N mice display reduced amyloid-β accumulation, improved neurogenesis, and important changes in brain cytokine expression compared with 5XFAD mice. Our results implicate neuronal p38α signalling in the synaptic plasticity dysfunction and memory impairment observed in 5XFAD mice, by regulating both amyloid-β deposition in the brain and the relay of this accumulation to mount an inflammatory response, which leads to the cognitive deficits.
Alzheimer’s disease (AD) is one of the most common forms of dementia, which is characterized by a severe and progressive neuronal loss leading to cognitive dysfunctions and death1. The accumulation of extracellular amyloid plaques, formed by the aggregation of amyloid-β (Aβ) peptides, is a hallmark of the disease2. Aβ peptides derive from the cleavage of the amyloid precursor protein (APP) by a β-secretase, known as β-site APP cleaving enzyme (BACE), and γ-secretase3,4. In non-pathological conditions, instead of BACE, APP is cleaved by α-secretase (TACE or ADAM10) preventing the formation of Aβ peptide5. Clearance of Aβ may occur by microglial phagocytosis or by Aβ degrading enzymes like neprilysin or insulin degrading enzyme (IDE)6. High levels of Aβ can activate glial cells leading to the release of pro-inflammatory cytokines7, as well as to impaired synaptic plasticity and to cognitive deficits8,9.
p38α is a protein kinase usually activated by environmental stresses, which can be also activated by other stimuli such as growth factors and inflammatory cytokines10. p38α and the related family member p38β are particularly abundant in brain11,12. Several studies have reported the activation of p38 signalling during normal aging13 as well as in age-related neurodegenerative diseases such as AD14, and experiments performed in vitro and in mice have shown that Aβ treatment induces the activation of the p38 pathway15,16. However, the precise biological function of p38 signalling in AD is not totally understood, and a recent report provided evidence for opposite roles of different p38 family members in AD pathogenesis17.
Synaptic plasticity is one of the most important properties of the mammalian brain as it underlies learning and memory processes. One of the main forms of synaptic plasticity found at the excitatory synapses is the long-term potentiation (LTP), which requires the activation of postsynaptic glutamate receptors (NMDA and AMPA) and is altered in neurodegenerative diseases18. Chemical inhibitors of p38 have been reported to improve the Aβ-mediated LTP impairment in vitro19,20. Importantly, chemical inhibitors that can penetrate the central nervous system and are highly selective for p38α in kinome screens have been shown to ameliorate spatial memory deficits both in mice infused with human Aβ1–42 peptide and in genetic mouse models of AD21,22,23. Pharmacological inhibition of p38α has been also reported to reduce pro-inflammatory cytokine levels in the brain of mice infused with Aβ1–42 peptide21 and in cultured primary microglia treated with Aβ1–4224.
The above reports are consistent with the idea that p38α-mediated production of cytokines by glial cells is critical for inflammation-induced neurotoxicity, which in turn increases the risk for cognitive dysfunction. However, in addition to the role of p38α in glia, there is evidence that neuronal p38α can also mediate some AD pathological effects. For example, inhibition of p38α but not p38β has been reported to protect cortical neurons in culture from neurotoxic insults including glutamate25, and neuronal p38α has been implicated in the suppression of LTP induced by IL-1β in organotypic hippocampal cultures26. Experiments using cultured neurons and chemical inhibitors have also correlated p38 signalling with Aβ production27. Therefore, genetically modified mice that are deficient for p38α specifically in neurons provide a valuable tool to better understand the mechanisms regulated by p38α that impinge on Aβ deposition and the associated pathological effects.
To investigate the role of neuronal p38α in AD-like phenotypic traits in vivo, we have used the five familial AD mutations (5XFAD) model, which overexpresses mutant human APP and presenilin-1 (PS1), and rapidly develops severe amyloid pathology followed by synapse degeneration and cognitive deficits28,29,30. We found that neuronal deletion of p38α suffices to improve synaptic plasticity and memory in 5XFAD mice. Our results suggest a role for neuronal p38α in the regulation of AD pathology at multiple levels, by modulating Aβ production, neuroinflammation and neurogenesis.
Neuronal p38α mediates cognitive dysfunctions
To investigate the role of p38α signalling in AD, we generated mice expressing CamkII-Cre and p38α-lox alleles (p38α∆-N). Downregulation of p38α did not affect the levels of p38β expressed in the brain (Supplementary Fig. S1a and S1b). Interestingly, p38α expression was higher in the hippocampus than in the cortex, whereas p38β showed the inverse expression pattern (Supplementary Fig. S1b). Adult p38α∆-N mice were healthy, showed no obvious phenotype and were also indistinguishable from the wild-type (WT) littermates in terms of non-cognitive and cognitive behaviour as illustrated by the novel object recognition test (Supplementary Fig. S1c and S1d).
We crossed the p38α∆-N mice with 5XFAD mice expressing two transgenes with AD clinical mutations, an early-onset AD mouse model28. Indeed, at 2–3 months of age, 5XFAD mice start to develop amyloid deposits and at 4–6 months display synaptic and memory dysfunctions28,29. The downregulation of p38α was confirmed by western blotting (Supplementary Fig. S1e). 5XFAD mice showed a lower body weight than WT mice, a difference that was maintained in the absence of neuronal p38α (Supplementary Fig. S1f). Gross brain morphology showed no significant differences between the three groups of animals (Supplementary Fig. S1g). Moreover, 5XFAD/p38α∆-N mice showed no changes in physical performance compared to 5XFAD mice, including motor activity, coordination, and grip strength (Supplementary Table S1).
We investigated the effect of neuronal-specific downregulation of p38α in the cognitive deficits of 5XFAD mice. To evaluate short- and long-term memory, mice were subjected to the novel object recognition test. In the training phase, animals were exposed to two identical objects for 10 min (Fig. 1a). We found that regardless of the genotype, 2 h after the training phase all animals were able to distinguish the novel object from the familiar one (Fig. 1b). Interestingly, 24 h later, 5XFAD mice were clearly impaired in their ability to distinguish the novel object, whereas 5XFAD/p38α∆-N mice behaved very similar to the WT mice (Fig. 1b), suggesting that p38α downregulation improved the memory deterioration observed in 5XFAD mice. Further analysis using the object location memory test and the social recognition test confirmed that elimination of p38α from neurons ameliorates the cognitive impairment produced by 5XFAD expression (Fig. 1c and d). These results indicate that the cognitive dysfunctions induced by 5XFAD transgenes at least partially depend on neuronal p38α signalling.
Neuronal p38α mediates synaptic plasticity alterations
AD mouse models are characterized by progressive synaptic depression and impaired LTP18. Moreover, cognitive dysfunction phenotypes usually correlate with deregulated synaptic protein expression and impaired synaptic plasticity31. To evaluate the implication of neuronal p38α on synaptic alterations, we used electrophysiological techniques to record CA3-to-CA1 synaptic transmission in hippocampal slices obtained from WT, 5XFAD and 5XFAD/p38α∆-N mice at 9 months of age, when synaptic deficits are already present in 5XFAD mice29. We found that basal synaptic transmission was reduced in 5XFAD mice, irrespective of the presence or absence of neuronal p38α (Fig. 2a). This result indicates that 5XFAD expression induces depressed transmission, as expected, but this alteration is not dependent on neuronal p38α. We then tested synaptic plasticity using a theta-burst protocol for LTP induction. WT animals displayed significant synaptic potentiation, whereas LTP was impaired in 5XFAD animals (p = 0.03 and p = 0.7, respectively). However, and in contrast with basal synaptic transmission, 5XFAD/p38α∆-N mice displayed significant LTP (p = 0.01) (Fig. 2b). These results suggest that neuronal p38α signalling contributes to the synaptic alterations that result in impaired synaptic plasticity in the 5XFAD mice.
To characterize the role of p38α in the deregulation of synaptic function, we analysed the expression of synaptophysin and PSD95, two proteins that play important roles in synapse maturation and synaptic plasticity32. We found that synaptophysin remained unchanged whereas PSD95 was significantly reduced in the hippocampus of 5XFAD mice compared to the WT littermates (Supplementary Fig. S2a). However, p38α downregulation did not restore the WT expression levels of PSD95. Expression of glutamate receptors GluA1 and GluN1 was also decreased in 5XFAD mice compared to WT mice (Supplementary Fig. S2b). However, the neuronal elimination of p38α had no effect in GluN1 expression, whereas GluA1 expression tent to increase but the results were not statistically significant. This decrease in postsynaptic proteins (PSD95, GluA1, GluN1) and its independence from p38α is consistent with the depression of basal transmission observed with 5XFAD and 5XFAD/p38α∆-N mice.
We also investigated the phosphorylation of GluA1 on Ser-831 and Ser-845, two residues that have been reported to potentiate AMPA receptor ion channel function33. We found that deletion of neuronal p38α in 5XFAD mice slightly increased Ser-831 phosphorylation, without affecting Ser-845 phosphorylation (Supplementary Fig. S2b). These results suggest that p38α could modulate the LTP response in 5XFAD mice through GluA1 phosphorylation on Ser-831.
Neuronal p38α regulates Aβ accumulation
The 5XFAD model is characterized by a rapid and strong Aβ accumulation in the brain. We looked for Aβ deposition in the brain of 12 months-old WT, 5XFAD and 5XFAD/p38α∆-N mice, by staining brain sections with a mouse anti-Aβ antibody (clone 4G8) that recognizes amino acid residues 17–24. As expected, 5XFAD mice presented a strong Aβ deposition in the cortex and hippocampus (Fig. 3a and b), and quantifications revealed that in both cases the density of Aβ staining was lower in 5XFAD/p38α∆-N mice than in 5XFAD mice (Fig. 3c).
In addition to the reduced Aβ deposits, we observed that 5XFAD/p38α∆-N mice showed similar levels of diffuse and dense plaques whereas the 5XFAD mice presented almost 60% more diffuse plaques (Fig. 3d). Since synaptic and cognitive dysfunctions are thought to be mediated by Aβ oligomers more than fibrillar plaques, we examined the level of Aβ oligomers in the brain. We found that hippocampus from 5XFAD/p38α∆-N mice displayed lower levels of Aβ oligomers than 5XFAD mice (Fig. 3e), suggesting a role for neuronal p38α signalling in the generation of Aβ oligomers in the brain in vivo. These results were confirmed by ELISA, which showed reduced Aβ40 and Aβ42 levels after neuronal p38α downregulation (Fig. 3f).
To investigate the mechanisms by which neuronal p38α regulates Aβ levels, we evaluated the expression of the main β-secretase BACE1. We found no significant differences in BACE1 protein levels in hippocampus from 12-month old mice of the three genotypes (Supplementary Fig. S3). However, in younger animals (5–6 months old), BACE1 expression was significantly increased in 5XFAD mice compared to WT mice and this effect was completely rescued in 5XFAD/p38α∆ mice (Fig. 4a). In addition to BACE1, α-secretases, such as ADAM10, can reduce Aβ levels5. We observed a slight decrease in the expression of the pro-form (pADAM10) accompanied with an increase of the mature form (mADAM10) of the ADAM10 protein between 5XFAD and 5XFAD/p38α∆-N mice (Fig. 4b). Finally, since Aβ degrading enzymes produced by glial cells can also regulate Aβ levels, we analysed the expression of neprilysin and IDE in 5–6-month old mice. We observed that both 5XFAD and 5XFAD/p38α∆-N mice expressed reduced levels of IDE in comparison with WT mice. In contrast, the expression of neprilysin was higher in the cortex from 5XFAD/p38α∆-N mice than in 5XFAD mice (Fig. 4c). Taken together, these results indicate that neuronal p38α may control Aβ production by regulating the expression of BACE and neprilysin.
Neuronal p38α modulates glial cell activation, cytokine production and neurogenesis
Glial cell activation is known to participate in Aβ clearance by phagocytosis and by producing different Aβ-degrading enzymes. Since we had observed changes in Aβ-degrading enzymes and secretase expression at early times, we immunostained activated microglia and astrocytes in the cortex and the hippocampus of 5–6-month old mice (Supplementary Fig. S4). Quantifications revealed increased staining for both Iba1 and GFAP (Fig. 5a) in 5XFAD mice compared to WT mice. Interestingly, we could measure a further increase in activated microglia and astrocytes in the 5XFAD/p38α∆-N mice compared with 5XFAD mice. This data is consistent with the idea that in the early stages of the disease, the absence of neuronal p38α may facilitate the activation of glial cells to induce Aβ degradation.
Since activated microglia can produce inflammatory cytokines such as TNFα, we investigated the implication of neuronal p38α deletion in cytokine production in 5XFAD mice. We found that cortical tissues from 5XFAD mice expressed higher levels of TNFα mRNA than WT mice (Fig. 5b). Interestingly, TNFα levels were reduced in the cortex of 5XFAD/p38α∆-N mice compared with 5XFAD mice (Fig. 5b), indicating a possible contribution of TNFα to the cognitive dysfunction induced by 5XFAD transgene expression. Further analysis identified three more cytokines, whose expression in cortex was significantly altered upon neuronal downregulation of p38α in 5XFAD mice (Fig. 5c). Granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-16 were both increased in 5XFAD mice compared to WT mice, and these changes were reversed in the 5XFAD/p38α∆-N mice. On the other hand, the chemokine CXCL12, also known as stromal cell-derived factor-1 (SDF-1), was reduced in the 5XFAD mice compared to WT mice, whereas 5XFAD/p38α∆-N mice showed similar levels as the WT mice. We confirmed by RT-PCR and ELISA that CXCL12 levels were decreased in the 5XFAD mice compared to the WT mice, and were partially rescued in 5XFAD/p38α∆-N mice (Fig. 5d). Thus, neuronal p38α signalling regulates the production of key cytokines in response to 5XFAD transgene expression.
There is evidence that neurogenesis is altered in the early stages of AD, which may contribute to synaptic dysfunction34,35. We found that the ability of dentate gyrus cells from 5XFAD/p38α∆-N mice to form both primary and secondary neurospheres was significantly increased in comparison with DG cells from 5XFAD mice (Fig. 6a and b). Moreover, we found an enhanced number of Ki67+ cells in the dentate gyrus of 5XFAD/p38αΔ-N mice compared with 5XFAD mice at both 5 and 12 months (Fig. 6c). These results suggest a role for p38α in the regulation of neural stem cells proliferation and self-renewal.
We have investigated the role of neuronal p38α signalling in the 5XFAD mouse model of AD. This model has been useful to study mechanisms linked to AD and to assay potential neuroprotective therapies. 5XFAD mice rapidly develop severe amyloid pathology followed by synapse degeneration and cognitive deficits28, with neuronal loss occurring at later stages36. We show that genetic deletion of p38α in neurons rescues the LTP and memory impairment of 5XFAD mice. These improvements are associated with a decrease in Aβ accumulation and reduced production of specific inflammatory cytokines.
The accumulation of Aβ in the brain is a critical event in AD pathology, and reflects an imbalance between its production and degradation. However, the cause of the imbalance is not totally understood. Studies in 5XFAD mice have contributed to establish the role of BACE1 in AD pathology. Thus, BACE1 deletion in 5XFAD mice shows neuroprotective effects, and it has been proposed that the amyloid pathway may trigger BACE1 elevation, which then drives a positive feedback loop that causes further amyloid generation37,38. Previous work has shown that chemical inhibition of stress-activated protein kinases including p38 impair BACE1 upregulation in cultured neurons exposed to 4-hydroxynonenal27. Moreover, a report published while we were preparing our work for submission, has shown that p38α downregulation using NEX-Cre decreases Aβ load and BACE1 expression in APP/PS1-expressing mice39. Our results are consistent with the idea that p38α signalling induces BACE-1 expression in adult neurons of 5XFAD mice.
We provide evidence that other mechanisms may also contribute to the reduced Aβ accumulation observed in 5XFAD/p38α∆-N mice. Thus, we detected increased expression of matured ADAM10 in 5XFAD mice with p38α-deficient neurons supporting that α-secretase-dependent cleavage of APP could avoid the cleavage by BACE1, therefore contributing to Aβ clearance. The absence of neuronal p38α could impinge on the ability of astrocytes to produce α-secretases, perhaps by regulating the secretion of soluble factors. Moreover, 5XFAD/p38α∆-N mice show increased expression of the Aβ-degrading enzyme neprilysin that correlates with astrocyte and microglial cell activation, which like neurons are known to express Aβ-degrading enzymes6. Of note, genetic downregulation of neprilysin increases Aβ deposition and aggravates the behavioural and neuropathological phenotype of 5XFAD mice40. Taken together, our results support that neuronal p38α may contribute to Aβ deposition in the brain both through the induction of BACE1 in a cell autonomous manner, and by reducing the recruitment or activation of glial cells that contribute to Aβ degradation.
Our study indicates that deletion of p38α in adult neurons suffices to rescue both LTP and memory loss in 5XFAD mice. Previous reports have shown that lowering BACE1 expression in 5XFAD mice, in addition to reducing Aβ levels, prevents LTP and memory deficits37,41,42. Taken together, it seems likely that p38α signalling in adult neurons regulates Aβ accumulation, which in turn induces synaptic plasticity dysfunction and cognitive deficits. However, it should be noted that p38α signalling can also contribute to Aβ-mediated LTP impairment, as shown in cortex and hippocampal slices treated with chemical inhibitors19,20. Of note, a recent report has shown that site-specific phosphorylation of Tau by p38γ reduces Aβ toxicity in AD mouse models17, which is the opposite effect of p38α. This emphasizes the importance of designing experiments that elucidate the function of specific p38 family members.
Inflammation plays an important role in the appearance and progression of AD, and 5XFAD mice show progressive neuroinflammation, which allowed to address different roles of microglia in the course of AD pathology43,44. Consistent with previous reports showing that systemic treatment with a brain-penetrant p38α chemical inhibitor reduces pro-inflammatory cytokine levels in the brain of mice treated with Aβ peptide21,22, we show that the increased levels of TNFα observed in 5XFAD mice are reduced in 5XFAD/p38α∆-N mice. Pro-inflammatory cytokines such as TNFα contribute to LTP inhibition, which can be mediated by p38 signalling8. Our results confirm the involvement of p38α signalling in LTP inhibition. This could be operating both at the level of TNFα production and by mediating the TNFα effect. Moreover, we show that impaired p38α signalling in adult neurons of 5XFAD mice also reduces GM-CSF levels. In astrocytes, p38α induces the expression of GM-CSF, which leads to the release of inflammatory cytokines and to neuronal death45. Our results indicate that p38α in neurons regulates GM-CSF production and the release of inflammatory cytokines such as TNFα implicated in LTP inhibition.
5XFAD/p38α∆-N mice show reduced expression of IL-16 compared with 5XFAD mice, and IL-16 is an important chemoattractant for T cell activation46. Little is known about the possible role of IL-16 in AD, although altered IL-16 levels have been reported in the plasma from AD patients suggesting that IL-16 may be implicated in the neuroinflammatory component of the disease47. Moreover, 5XFAD mice display reduced levels of CXCL12/SDF-1α, which are recovered upon neuronal p38α downregulation. CXCL12 is produced by astrocytes as well as by neurons and has been implicated in brain plasticity, but can also function as chemoattractant for lymphocytes and macrophages, and in neuro-glia communication48. Intracerebroventricular administration of CXCL12 reduces Aβ deposits in AD mice, which is associated with an increase of cells positive for the microglia marker Iba1, suggesting that CXCL12 recruits migroglia cells to induce Aβ clearance49. Since the reduced Aβ levels and increased microglia and astrocyte activation observed in 5XFAD/p38α∆-N mice correlate with partially restored CXCL12 levels, it is possible that CXCL12 downregulation by neuronal p38α contributes to Aβ accumulation. Moreover, impaired signalling by the CXCL12 receptor CXCR4 has been associated to cognitive decline50, suggesting that increased CXCL12 levels could also contribute to the improved memory of 5XFAD/p38α∆-N mice.
There is evidence indicating that hippocampal neurogenesis is impaired in mouse models of AD including 5XFAD mice51. This could be responsible, at least in part, for neuronal vulnerability as well as for the synaptic plasticity deficit and memory loss observed in AD34. We have found that p38α downregulation in neurons ameliorates the impaired neurogenesis of 5XFAD mice. Of note, CXCL12/CXCR4 signalling has been described to regulate neurogenesis during embryo development52, and in adult brain to counteract local damage53. Therefore, p38α signalling might contribute to the impaired neurogenesis associated with brain pathologies such as AD.
In summary, p38α downregulation in adult neurons of 5XFAD mice results in decreased Aβ accumulation, probably by a mechanism dependent on the modulation of both BACE1 and Aβ degrading enzymes. This Aβ decrease is associated with reduced levels of pro-inflammatory cytokines in brain, as well as restored LTP and improved memory response. It would be interesting to test the role of neuronal p38α in AD mouse models that do not overexpress APP54. Taken together, our results indicate that p38α signalling in neurons may participate in the regulation of both Aβ deposition in the brain and the deleterious effects of Aβ accumulation, further supporting the potential interest of targeting p38α for the treatment of AD.
To induce forebrain-specific downregulation of p38α, B6.Cg-Tg(Camk2a-cre)T29-1Stl/J mice obtained from the Jackson Laboratory (Bar Harbor, ME, USA) were bred with p38α-floxed mice in C57BL/6 background55,56. Animals for experimentation were maintained in C57BL/6 background and were obtained by crossing p38α (lox/lox) Camk2a-Cre males or females with p38α (lox/lox) mice of the opposite sex. To combine the forebrain-specific p38α deletion with the 5XFAD model, we used heterozygous 5XFAD transgenic mice purchased from The Jackson Laboratory. These mice overexpress in the brain mutant human APP(695) with the Swedish (K670N, M671L), Florida (I716V), and London (V717I) Familial Alzheimer’s Disease (FAD) mutations along with human PS1 harbouring two FAD mutations, M146L and L286V, bot transgenes driven by the mouse Thy1 promoter. We crossed 5XFAD Tg/+ males (B6SJL background) with p38α (lox/lox) females (C57BL/6 background), and the resulting 5XFAD Tg/+p38α (lox/+) males were crossed again with p38α (lox/lox) females to obtain 5XFAD Tg/+p38α (lox/lox) mice. For experimentation, 5XFAD Tg/+p38α (lox/lox) males were crossed with p38α (lox/lox) Camk2a-Cre females to obtain 5XFAD Tg/+p38α (lox/lox) mice with or without Cre. Littermate mice that do not express the 5XFAD transgene were used as controls. We did not detect significant fertility problems in p38α (lox/lox) Camk2a-Cre mice or 5XFAD Tg/+p38α (lox/lox) Camk2a-Cre mice. Mice were genotyped for MAPK14 (p38α), Camk2a-Cre and 5XFAD by gene-specific PCRs using tail genomic DNA. Primers and conditions are available upon request. Mice were maintained and handled according to national and European Union regulations.
Mice were handled in compliance with the relevant national and international guidelines following protocols approved by the Animal Care Ethic Committee of Barcelona University.
Novel object recognition test
This test evaluates short- and long-term recognition memory involving hippocampus and cerebral cortical areas57,58. The experimental apparatus used for this test was a 90°, two-arm, 25-cm-long, 20-cm-high, and 5-cm-wide maze made of black polyvinyl chloride. A video camera hanging from the ceiling recorded the mouse movement for their posterior analysis. This test consisted of a period of habituation, an acquisition trial and two test trials (2 h and 24 h after the acquisition trial). During habituation, the mouse was allowed to freely explore the apparatus without objects, for 10 min on two consecutive days. On the acquisition trial of the next day, two identical novel objects (A + A′) were placed at the end of each arm, and the animal was allowed to explore them freely for 10 min. The mouse was then removed from the apparatus and returned to its home cage. Two h after the acquisition trial, one of the objects was replaced by a novel object with a different shape and colour (A + B), and the mouse was allowed to explore the maze for another 10 min. Twenty-four h after the acquisition trial, the mice were tested again, with a new object and an object identical to the new one in the previous trial (B + C). The time spent exploring each object was quantified from the video recordings from each trial session. Exploration of an object was defined as pointing the nose towards the object at a distance ≤1 cm and/or touching it with the nose. Turning around or sitting on an object was not considered exploration. To analyse cognitive performance in each trial, the percentage of time that mice spent exploring the novel and familiar object over the total time spent exploring both objects were calculated.
Object location test
This test evaluates spatial memory, a hippocampal-dependent task58,59,60. The experimental apparatus used for this test was an open-field box (40 cm wide × 30 cm deep × 30 cm high) made of black polyvinyl chloride with a video camera hanging from the ceiling to record the mouse movement. Identical plastic columns (10 cm in height ×5 cm in diameter) were used as objects. This test consisted of a period of habituation, an acquisition trial and a test trial. During habituation, the mice were allowed to freely explore the apparatus without objects, for 10 min on the day before the acquisition trial. On the acquisition trial, each mouse was allowed 5 min to explore two identical objects (A1 + A2) that were placed in the corners of the experimental apparatus. The mouse was then removed from the apparatus and returned to its home cage. The test trial was conducted 1 h after the acquisition trial. On the test trial, one of the objects (A2) was moved to a different location (A2′) and the other object (A1) retained in the same position (A1) as in the acquisition trial. The mouse was reintroduced into the experimental apparatus for 5 min, and the time spent exploring each object (A1 + A2′) was recorded again. Exploration of an object was defined as pointing the nose towards the object at a distance of ≤1 cm and/or touching it with the nose. Turning around or sitting on an object was not considered exploration. To analyse cognitive performance, the percentage of time that mice spent exploring the displaced and non-displaced object over the total time spent exploring both objects were calculated.
Social recognition test
This test evaluates social recognition memory, another hippocampal-dependent task61,62. The test consisted of a period of habituation, an initial trial and a test trial 3 h after the initial trial. During habituation, the adult male mice to be tested were placed into a clean individual cage (the same acrylic cage used for housing) and allowed to freely explore it for 15 min prior to the experimental sessions. On the initial trial, a male juvenile mouse was placed into the cage with the test mouse for 2 min. The juvenile mouse was then returned to its home cage. After 3 h, the same juvenile mouse was placed back into the test mouse’s cage for another 2 min. The time spent investigating the juvenile by the test mouse was quantified from each trial session. Social investigation behaviour includes direct contact with the juvenile, sniffing of the mouth, ears, tail, ano-genital area, and close following (within 1 cm) of the juvenile. Any aggressive encounter between animals was immediate cause for terminating the experiment and excluding data from the analysis. To measure social recognition memory, the percentage of time that mice spent investigating the juvenile during the test trial divided by the initial investigation time (% investigation) was calculated.
Acute hippocampal slices of 400 μm-thickness were obtained from 9 month old male mice (WT, 5XFAD and 5XFAD/p38α∆-N), with a dissection solution containing 10 mM D-glucose, 4 mM KCl, 26 mM NaHCO3, 233.7 mM sucrose, 5 mM MgCl2. Slices were then maintained for 1 h at 32 °C in artificial cerebrospinal fluid (ACSF) before recordings. ACSF contained 119 mM NaCl, 2.5 mM KCl, 26 mM NaHCO3, 1 mM NaH2PO4, 11 mM D-glucose, 2.5 mM CaCl2, 1.2 mM MgCl2, saturated with 95% O2/5% CO2. Synaptic responses were evoked with bipolar stimulation electrodes and recorded with a low-resistance (0.2–0.8 MΩ) glass electrode filled with ACSF, placed in CA1 stratum radiatum. Field excitatory postsynaptic potentials (fEPSPs) were recorded at different stimulation intensities for each slice to generate an input-output curve. This curve was also used to set the baseline fEPSP value at ≈30% of the maximum for LTP experiments. Baseline stimulation was delivered every 15 sec (0.01 msec duration pulses) for at least 20 min before LTP induction to ensure stability of the response. LTP was induced with a theta-burst stimulation protocol: bursts of 4 pulses at 100 Hz, with the bursts repeated in 10 trains at 5 Hz, and the trains repeated 4 times separated by 15 sec.
Animals were weighted and decapitated; immediately the brain was harvested and separated sagitally in two hemispheres. One hemibrain was fixed overnight by immersion in 4% paraformaldehyde (PFA) at 4 °C and embedded in paraffin. The other hemibrain was dissected on ice to obtain hippocampus and cerebral cortex and samples were stored at −80 °C for further analysis. One week after the object recognition test, half of the animals were weighted and decapitated. The brain was dissected on ice to obtain hippocampus and cerebral cortex and samples were stored at −80 °C for further analysis. The other half was anesthetized by intraperitoneal injection of ketamine (150 mg/kg) and xylazine (10 mg/kg) and then transcardially perfused with PBS followed by 4% of PFA. Afterwards, brains were dissected, post-fixed overnight in 4% PFA at 4 °C and embedded in paraffin.
The levels of soluble amyloid-β40 and amyloid-β42 were analysed in cerebral cortex tissues using the ELISA kits from Invitrogen KHB3481 and KHB3441, respectively, following the manufacturer’s instructions.
To detect cytokine levels in the brain, cortical tissues were isolated from 4 different mice of the same genotype and prepared as described in the mouse cytokine array’s protocol (R&D systems, ARY006). Briefly, the array, which contained 40 different antibodies printed in duplicate, was incubated overnight at 4 °C with 300 μg of cortex lysate. After several washes, the array was incubated for 30 min with streptavidin-horseradish peroxidase and membranes were exposed to chemiluminescent reagent mix. Positive spots were detected by autoradiography according to the manufacturer’s instructions and quantify by Image J software.
TNFα and CXCL12 ELISA
The levels of TNFα and CXCL12 were analysed in cerebral cortex tissue using ELISA kits from Invitrogen (KMC3011) and from R&D systems (MCX120), respectively, following the manufacturer’s instructions. Brain samples were prepared as described for the cytokine array and 200–500 μg of brain extracts were used for quantification.
RNA extraction and real-time PCR
Total RNA from cerebral cortex and hippocampus tissues was isolated using the PureLink RNA mini kit (Ambion #12183018A) according to the manufacturer’s protocol and treated with DNase (PureLink DNAse; Invitrogen). RNA was quantified using a Nanodrop spectrophotometer. An aliquot of 1 μg of total RNA was reversed-transcribed (SuperScript II; Invitrogen #18064–014) and used as a template for real-time PCR. The reactions were performed in triplicate using 4 μl of 1/10 diluted cDNA on a Bio-Rad C1000 thermal cycler machine using SYBR Green (Bio-Rad, 48190–011). Relative quantities (∆ cycle threshold values) were obtained by normalizing against Rpl32. The primers used are listed in the Supplementary Table S2.
Cerebral cortex and hippocampal tissues were mechanically disrupted in lysis buffer containing 20 mM Tris/HCl pH 7.4, 150 mM NaCl, 4 mM EDTA, 0.5% Triton X-100, 0.2% SDS, 20 mM NaF, 0.1 mM sodium orthovanadate, 2 mM PMSF, 1 μM microcystin, 1 mM DTT, Protease Inhibitor Cocktail Set III (Merck Millipore) and PhosStop Phosphatase inhibitor cocktail (Roche). The homogenate was incubated on ice for 15 min, sonicated and centrifuged at 4 °C for 10 min at 16,000 xg. Protein content was quantified using the Protein Assay kit (Bio-Rad) with BSA as standard, and 20–50 μg of total protein lysate were separated on SDS-PAGE and transferred to a nitrocellulose membrane. After blocking (5% non-fat milk and 1% BSA in PBS, 1 h at RT) membranes were incubated at 4 °C overnight with the primary antibodies listed in the Supplementary Table S3. After washing with PBS, membranes were incubated with Alexa Fluor 680 or 800-conjugated secondary antibodies (Molecular Probes; 1:3000) for 1 h at RT and were visualized using Odyssey Infrared Imaging System (Li-Cor, Biosciences). Band intensities were quantified by densitometric analysis using β-actin as loading control. For the detection of Aβ, protein lysates were separated in a NuPAGE® Novex® 4–12% Bis-Tris Gels (Invitrogen, NP0336BOX). After transfer to nitrocellulose, membranes were boiled for 5 min in PBS, blocked and incubated at 4 °C overnight with the primary antibodies. After washing with PBS, membranes were incubated with HRP conjugated anti-mouse (Dako, P0447) for 1 h at RT, and exposed to chemiluminescent reagent mix (Millipore, WBKLS0050).
Histology and immunohistochemistry
For histological analysis, mice were anesthetized by intraperitoneal injection of ketamine (150 mg/kg) and xylazine (10 mg/kg) and then transcardially perfused with PBS followed by 4% of paraformaldehyde (PFA). Afterwards, brains were dissected, post-fixed overnight in 4% PFA at 4 °C and embedded in paraffin. Paraffin-embedded brain sections were stained with Hematoxylin/Eosin (H&E) and cresyl violet in order to analyse brain morphology. Immunostainings were performed for 1–2 h at RT using antibodies against amyloid-β 4G8 (Covance, SIG-39320, 1/50), Iba1 (Wako, 019–19741, 1:2000), GFAP (Dako, Z0334, 1:800), Ki67 (Novocastra, Ki67P-CE, 1:1000). The secondary antibodies were HRP conjugated anti-rabbit (ImmunoLogic, DPVR110HRP, RTU), anti-mouse (Dako, P0447; 1:100), anti-goat (Dako, P0449; 1:80) and anti-rat (Dako, P0450; 1:75) and were all incubated for 30–45 min at RT. Signals were visualized with DAB (3,3-diaminobenzidine), using hematoxilin as a counterstaining.
Brain pictures were acquired using an inverted Leica DM4000B microscope and analysed using Leica application suite software. The number and type of amyloid plaques in the hippocampus were manually defined and quantified. Dense plaques were identified by the presence of dense core whereas diffuse plaques were identified by the presence of diffuse corona, as illustrated in Fig. 3d.
Mice were handled in compliance with the relevant national and international guidelines following protocols approved by the Animal Care Ethic Committee of the Biodonostia Institute. Nine-months old 5XFAD and 5XFAD/p38α∆-N mice were euthanized by CO2 inhalation and brains were excised and placed in ice-cold PBS (n = four per genotype). The tissue containing the DG was carefully dissected out and homogenized in DMEM-F12 medium containing 10% papain (Roche, 10108014001) and 1% DNAse (Promega, M6101), passed through a 40 μM filter to obtain a single cell suspension, and plated in triplicates in six well culture dishes at a density of 105 cells/well in DMEM-F12 complete culture media (Fisher, 11514436) supplemented with 1% glutamine (Teknovas, A1125030024), 100 units/ml penicillin and 100 μg/ml streptomycin (Teknovas, A3915140122), 1.37% glucose (Sigma, G8769), 1% N2 (Teknovas, 11520536), 2% B27 (Teknovas, 11500446), 20 ng/ml EGF (Gibco, A15E9644), and 20 ng/mL bFGF (Gibco, A15F0291). At day 10, primary neurospheres were counted. Then cells were disaggregated with accutase (Fisher, A1110501) and cultured for additional 10 days before counting secondary neurospheres.
Results are expressed as mean ± SEM of the indicated number of independent experiments. For statistical comparisons among groups, p values were calculated using Student’s t‐test or with one-way ANOVA followed by Bonferroni’s multiple comparison test. Differences were considered statistically significant when p < 0.05 (*p < 0.05; **p < 0.01; ***p < 0.001).
How to cite this article: Colié, S. et al. Neuronal p38α mediates synaptic and cognitive dysfunction in an Alzheimer's mouse model by controlling β-amyloid production. Sci. Rep. 7, 45306; doi: 10.1038/srep45306 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Huang, Y. & Mucke, L. Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204–1222 (2012).
Ittner, L. M. & Gotz, J. Amyloid-beta and tau–a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci 12, 65–72 (2011).
De Strooper, B., Vassar, R. & Golde, T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6, 99–107 (2010).
Haass, C., Kaether, C., Thinakaran, G. & Sisodia, S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2, a006270 (2012).
Saftig, P. & Lichtenthaler, S. F. The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain. Progress in neurobiology 135, 1–20 (2015).
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S. & Love, S. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 70, 944–959 (2011).
Selkoe, D. J. Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3, 75–80 (2001).
Wang, Q., Wu, J., Rowan, M. J. & Anwyl, R. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 22, 2827–2832 (2005).
Rowan, M. J., Klyubin, I., Wang, Q. & Anwyl, R. Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. Exp Gerontol 39, 1661–1667 (2004).
Cuadrado, A. & Nebreda, A. R. Mechanisms and functions of p38 MAPK signalling. Biochem J 429, 403–417 (2010).
Jiang, Y. et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 271, 17920–17926 (1996).
Lee, S. H., Park, J., Che, Y., Han, P. L. & Lee, J. K. Constitutive activity and differential localization of p38alpha and p38beta MAPKs in adult mouse brain. J Neurosci Res 60, 623–631 (2000).
Hu, D., Serrano, F., Oury, T. D. & Klann, E. Aging-dependent alterations in synaptic plasticity and memory in mice that overexpress extracellular superoxide dismutase. J Neurosci 26, 3933–3941 (2006).
Hensley, K. et al. p38 kinase is activated in the Alzheimer’s disease brain. Journal of neurochemistry 72, 2053–2058 (1999).
Takuma, K. et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci U S A 106, 20021–20026 (2009).
Chang, K. H. et al. Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer’s disease. Journal of neurochemistry 113, 1221–1229 (2010).
Ittner, A. et al. Site-specific phosphorylation of tau inhibits amyloid-beta toxicity in Alzheimer’s mice. Science 354, 904–908 (2016).
Pozueta, J., Lefort, R. & Shelanski, M. L. Synaptic changes in Alzheimer’s disease and its models. Neuroscience 251, 51–65 (2013).
Wang, Q., Walsh, D. M., Rowan, M. J., Selkoe, D. J. & Anwyl, R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24, 3370–3378 (2004).
Origlia, N. et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 28, 3521–3530 (2008).
Munoz, L. et al. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer’s disease mouse model. J Neuroinflammation 4, 21 (2007).
Watterson, D. M. et al. Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. PLoS One 8, e66226 (2013).
Roy, S. M. et al. Targeting human central nervous system protein kinases: An isoform selective p38alphaMAPK inhibitor that attenuates disease progression in Alzheimer’s disease mouse models. ACS Chem Neurosci 6, 666–680 (2015).
Bachstetter, A. D. et al. Microglial p38alpha MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Abeta). J Neuroinflammation 8, 79 (2011).
Xing, B., Bachstetter, A. D. & Van Eldik, L. J. Inhibition of neuronal p38alpha, but not p38beta MAPK, provides neuroprotection against three different neurotoxic insults. J Mol Neurosci 55, 509–518 (2015).
Tong, L. et al. Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1beta via p38 mitogen-activated protein kinase. J Neurosci 32, 17714–17724 (2012).
Tamagno, E. et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. Journal of neurochemistry 92, 628–636 (2005).
Oakley, H. et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129–10140 (2006).
Kimura, R. & Ohno, M. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol Dis 33, 229–235 (2009).
Rojas, S. et al. In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. Neurobiol Aging 34, 1790–1798 (2013).
Walsh, D. M. & Selkoe, D. J. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 44, 181–193 (2004).
El-Husseini, A. E., Schnell, E., Chetkovich, D. M., Nicoll, R. A. & Bredt, D. S. PSD-95 involvement in maturation of excitatory synapses. Science 290, 1364–1368 (2000).
Lee, H. K., Barbarosie, M., Kameyama, K., Bear, M. F. & Huganir, R. L. Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 405, 955–959 (2000).
Mu, Y. & Gage, F. H. Adult hippocampal neurogenesis and its role in Alzheimer’s disease. Mol Neurodegener 6, 85 (2011).
Rodriguez, J. J. & Verkhratsky, A. Neurogenesis in Alzheimer’s disease. J Anat 219, 78–89 (2011).
Eimer, W. A. & Vassar, R. Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation. Mol Neurodegener 8, 2 (2013).
Ohno, M. et al. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis 26, 134–145 (2007).
Zhao, J. et al. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer’s disease pathogenesis. J Neurosci 27, 3639–3649 (2007).
Schnoder, L. et al. Deficiency of Neuronal p38alpha MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1. J Biol Chem 291, 2067–2079 (2016).
Huttenrauch, M. et al. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer’s disease. J Alzheimers Dis 44, 1291–1302 (2015).
Kimura, R., Devi, L. & Ohno, M. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer’s disease transgenic mice. Journal of neurochemistry 113, 248–261 (2010).
Devi, L. & Ohno, M. Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer’s disease model mice. Eur J Neurosci 31, 110–118 (2010).
Wang, Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell 160, 1061–1071 (2015).
Spangenberg, E. E. et al. Eliminating microglia in Alzheimer’s mice prevents neuronal loss without modulating amyloid-beta pathology. Brain 139, 1265–1281 (2016).
Zaheer, A. et al. A novel role of glia maturation factor: induction of granulocyte-macrophage colony-stimulating factor and pro-inflammatory cytokines. Journal of neurochemistry 101, 364–376 (2007).
Cruikshank, W. & Little, F. lnterleukin-16: the ins and outs of regulating T-cell activation. Crit Rev Immunol 28, 467–483 (2008).
Motta, M., Imbesi, R., Di Rosa, M., Stivala, F. & Malaguarnera, L. Altered plasma cytokine levels in Alzheimer’s disease: correlation with the disease progression. Immunol Lett 114, 46–51 (2007).
Guyon, A. CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front Cell Neurosci 8, 65 (2014).
Wang, Q. et al. Stromal cell-derived factor 1alpha decreases beta-amyloid deposition in Alzheimer’s disease mouse model. Brain Res 1459, 15–26 (2012).
Parachikova, A. & Cotman, C. W. Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease. Neurobiol Dis 28, 143–153 (2007).
Moon, M., Cha, M. Y. & Mook-Jung, I. Impaired hippocampal neurogenesis and its enhancement with ghrelin in 5XFAD mice. J Alzheimers Dis 41, 233–241 (2014).
Lu, M., Grove, E. A. & Miller, R. J. Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. Proc Natl Acad Sci USA 99, 7090–7095 (2002).
Li, M., Hale, J. S., Rich, J. N., Ransohoff, R. M. & Lathia, J. D. Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair. Trends Neurosci 35, 619–628 (2012).
Saito, T. et al. Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci 17, 661–663 (2014).
Ventura, J. J. et al. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 39, 750–758 (2007).
Heinrichsdorff, J., Luedde, T., Perdiguero, E., Nebreda, A. R. & Pasparakis, M. p38 alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure. EMBO Rep 9, 1048–1054 (2008).
Broadbent, N. J., Gaskin, S., Squire, L. R. & Clark, R. E. Object recognition memory and the rodent hippocampus. Learn Mem 17, 5–11 (2010).
Barker, G. R. & Warburton, E. C. Object-in-place associative recognition memory depends on glutamate receptor neurotransmission within two defined hippocampal-cortical circuits: a critical role for AMPA and NMDA receptors in the hippocampus, perirhinal, and prefrontal cortices. Cereb Cortex 25, 472–481 (2015).
Murai, T., Okuda, S., Tanaka, T. & Ohta, H. Characteristics of object location memory in mice: Behavioral and pharmacological studies. Physiol Behav 90, 116–124 (2007).
Assini, F. L., Duzzioni, M. & Takahashi, R. N. Object location memory in mice: pharmacological validation and further evidence of hippocampal CA1 participation. Behav Brain Res 204, 206–211 (2009).
Kogan, J. H., Frankland, P. W. & Silva, A. J. Long-term memory underlying hippocampus-dependent social recognition in mice. Hippocampus 10, 47–56 (2000).
Garrido Zinn, C. et al. Major neurotransmitter systems in dorsal hippocampus and basolateral amygdala control social recognition memory. Proc Natl Acad Sci USA 113, E4914–4919 (2016).
We are grateful to Elisabeth Llonch for excellent technical assistance with immunohistochemistry analysis, Emma Richet for support and helpful discussions and Natalia Carullá for useful suggestions to analyse Aβ expression. This work was supported by the CONSOLIDER grant CSD2010-0045 from the Spanish Ministerio de Economia y Competitividad (MINECO). S.C. was partly supported by the European Union Seventh Framework Programme (FP7/Marie Curie Actions/COFUND). IRB Barcelona is the recipient of a Severo Ochoa Award of Excellence from MINECO (Government of Spain).
The authors declare no competing financial interests.
About this article
Cite this article
Colié, S., Sarroca, S., Palenzuela, R. et al. Neuronal p38α mediates synaptic and cognitive dysfunction in an Alzheimer’s mouse model by controlling β-amyloid production. Sci Rep 7, 45306 (2017). https://doi.org/10.1038/srep45306
Acute Pannexin 1 Blockade Mitigates Early Synaptic Plasticity Defects in a Mouse Model of Alzheimer’s Disease
Frontiers in Cellular Neuroscience (2020)
A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse
Alzheimer's Research & Therapy (2020)
The key genes, phosphoproteins, processes, and pathways affected by efavirenz‐activated CYP46A1 in the amyloid‐decreasing paradigm of efavirenz treatment
The FASEB Journal (2019)
Aging Cell (2019)
Astrocytic p38α MAPK drives NMDA receptor-dependent long-term depression and modulates long-term memory
Nature Communications (2019)